Tharimmune presents positive clinical data at aasld the liver meeting(r) to support th104 for chronic pruritus in chronic liver disease

Significant correlation shown between blood levels and symptom relief; th104 was well tolerated with no unexpected treatment-emergent adverse events phase 2 preliminary data for chronic pruritus in primary biliary cholangitis expected in 2025 bridgewater, nj / accesswire / november 18, 2024 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, presented new th104 clinical data at the american association for the study of liver disease (aasld) the liver meeting® 2024, underway in san diego from november 15-19. the phase 1 trial was a single-dose, single-center, open-label, randomized study of th104 transmucosal buccal film conducted in two cohorts of patients with chronic liver disease (cld), with the primary outcome of safety and tolerability.
THAR Ratings Summary
THAR Quant Ranking